(PRA and PRC), renal and cardiac hypertrophy in NALP3 and ASC deficient mice on which the two-kidney, one clip (2K1C) and the deoxycorticosterone-acetate (DOCA)/salt models were applied. MBP, PRA, PRC, and HW/BW were significantly increased at week 12 in WT-2K1C mice compared to the sham. Neither NLAP3-KO nor ASC-KO 2K1C treated mice developed hypertension and had lower circulating levels of PRA and PRC and serum amyloid A (SAA) and IL6 compared to the control. RNA levels of SAA, NLRP3, IL1b and IL1a were increased in the ischemic kidney in C57BL/6J mice. Administration of anti-IL1b antibody to the WT mice attenuated the increases of blood pressure and renin in 2K1C mice. With chronic administration of DOCA/salt, MBPs in both NLRP3-KO and WT mice were comparable and not significantly increased compared to tap water group. PRA and PRC in both NALP3-KO and WT mice were significantly suppressed by DOCA/salt. HW/BW and KW/BW in both DOCA/salt treated NALP3-KO and WT mice were significantly increased. DOCA/salt induced hypokalemia was comparable between Nlrp3 KO and WT groups. However, the heart and kidney index in DOCA/salt NLRP3-KO mice was significantly lower than that in DOCA/salt WT mice. Our data show that NLRP3 mediated IL1b is linked to development of renovascular hypertension and suggest that a novel target for the treatment of hypertension. The results also implicate that NLRP3 contributes to the development of cardiac and renal hypertrophy independently of blood pressure in the DOCA/salt model. Chronic kidney disease (CKD) and obesity are important public health concerns. We examined the influence of dietary management and physical exercises on renal function, lipid profiles and exercise tolerance of a group of CKD patients. We enrolled 45 obese patients with CKD from stage 1 to 3b with tailored by regular dietitian consultation, recommendations of adequate daily protein and caloric intake, and physical exercises for body weight (BW) reduction. The target was BW reduction Z 3%. Thirty eight obese CKD patients completed the study and 24 patients reached the target. Patients who reached the target was significant larger in total body fat decrement than those who failed (3.0% vs 0.5%, p ¼ 0.003). In addition, total muscle mass, especially on trunk and lower limbs (1.2% vs 0%, P ¼ 0.026) was significant decreased in patients who reached the target compared to those who failed. The laboratory data disclosed the significant reduction of Chol (0.7% vs. -19.3%; P ¼ 0.007), LDL-C ( 3.7% vs. -37.6%; P o 0.001), and UA (0% vs. -0.8%; P ¼ 0.025) between the two groups. The cardiorespiratory endurance to complete 800 meters run (375.1 7 64.7 sec vs. 327.1 7 84.0 sec; P ¼ 0.001), abdominal muscle strength and endurance by times of sit-ups (13.6 7 9.1 number/min vs. 19.9 7 9.2; P ¼ 0.005), and flexibility of the lower back by sit and reach (18.8 7 10.8 cm vs. 27.8 7 10.9 cm; Po 0.001) of the patients who reached the target were improved significantly after 2-months of physical exercise training and education.We conclude that combination of dietary management and exercises are effective in improving health-related physical fitness, blood pressure control, dyslipidemia and renal function in overweight or obese CKD patients. Supportive individualized programs for lifestyle change could exert beneficial effects. A longitudinal study with larger sample size is warranted to elucidate the efficacy of combination of dietary management and exercises. Hypertension is a major cause of chronic kidney disease. Recent studies have shown that inflammation plays a critical role in the pathogenesis and progression of hypertensive kidney disease. However, the signaling mechanisms underlying the induction of inflammation are poorly understood. We have found that CXCL16, a recently discovered chemokine, is induced in the kidney in a murine model of angiotensin II (Ang II)-induced hypertension. Therefore, we examined whether CXCL16 regulates inflammatory cell infiltration and renal injury using CXCL16 knockout (CXCL16-KO) mice. Wildtype (WT) and CXCL16-KO mice were treated with Ang II via subcutaneous osmotic minipumps at 1500 ng/kg/min for up to 4 weeks. To accelerate renal injury, all mice were subjected to unilateral nephrectomy and received 1% NaCl in drinking water. WT and CXCL16-KO mice had virtually identical blood pressure at baseline. Ang II treatment led to an increase in blood pressure that is similar between WT and CXCL16-KO mice. Diabetic nephropathy is one of the most important causes of end stage renal disease (ESRD) in the world. Recently in a multicenter, randomized clinical trial performed in China, it was found that compound a-keto acid tablet in combination with low protein diet(LPDþKA) reduced proteinuria and delayed the progression to ESRD in Type 2 diabetic nephropthy(T2DN). However, the mechanisms underlined these effects were not been elucidated. This study is a part of the continuation of the study to explore the effects of LPDþ KA on podocyte as well as on local RAS in the kidney. A total of 60 patients with T2DN and CKD stages 3-4 are included in this study. All patients are treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day. The diet is randomly supplemented with keto-amino acids (Ketosterils, Fresenius Kabi) at a dosage of 100 mg/kg BW per day. The other 30 patients receive placebo. After six months of follow-up, protein intake differed only by 0.07 g/ kg/day between the two groups. The mean declines in GFR were 4.2 mL/min/ year (95%CI;2.9 to 5.5) in LPD group and 3.7 (95%CI; 2.7 to 4.7) in LPDþKA group. Compared with LPD, paitients in LPDþKA group had reduced proteinuria (2.1670.4 vs 3.5670.6 g/day; p/0.05). However, serum albumin and prealbumin levels did not change. Through further research we found that, after a median follow-up for six months, the urinary angiotensinogen:creatinine ratio in LPD patients was higher than in LPDþKA subjects (10.1 73.2 mg/g vs 5.8 7 1.2 mg/g; p/0.05);The urinary mRNA levels of the target genes nephrin, podocin and synaptopodin of podocyte were higher in the LPD group compared with LPDþKA(p/0.05) in urinary sediment, and the expression of nephrin, podocin and synaptopodin mRNA positively correlated with serum creatinine (r¼ 0.326, p ¼ 0.04; r ¼ 0.426, p ¼ 0.03; r ¼ 0.343, p ¼ 0.001, respectively). In conclusion, compound a-keto acid tablet in combination with low protein diet (LPDþ KA) is associated with amelioration of proteinuria, better reduction in the loss of kidney function compared with LPD alone meanwhile nutrition status remained well. The mechanism under these effects may be explained by the role of LPDþ KA diet in reducing urine podocyte loss and lowering the angiotensinogen level in the urine. It is critical to preserve residual renal function (RRF) in CAPD, as RRF is associated with lower morbidity and mortality. low-protein diet supplemented with a-keto acids was reported to have an important roles in delaying in follow-up period progression of renal failure and relieving malnutritional status in non-dialysis patients with chronic renal failure. We evaluate the effects on the nutritional status and RRF of a low-protein diet supplemented with a-keto acids on CAPD patients prospectively. Seventy eight CAPD patients who were
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Chronic kidney disease (CKD) and obesity are important public health concerns. We examined the influence of dietary management and physical exercises on renal function, lipid profiles and exercise tolerance of a group of CKD patients. We enrolled 45 obese patients with CKD from stage 1 to 3b with tailored by regular dietitian consultation, recommendations of adequate daily protein and caloric intake, and physical exercises for body weight (BW) reduction. The target was BW reduction Z 3%. Thirty eight obese CKD patients completed the study and 24 patients reached the target. Patients who reached the target was significant larger in total body fat decrement than those who failed (3.0% vs 0.5%, p ¼ 0.003). In addition, total muscle mass, especially on trunk and lower limbs (1.2% vs 0%, P ¼ 0.026) was significant decreased in patients who reached the target compared to those who failed. The laboratory data disclosed the significant reduction of Chol (0.7% vs. -19.3%; P ¼ 0.007), LDL-C ( 3.7% vs. -37.6%; P o 0.001), and UA (0% vs. -0.8%; P ¼ 0.025) between the two groups. The cardiorespiratory endurance to complete 800 meters run (375.1 7 64.7 sec vs. 327.1 7 84.0 sec; P ¼ 0.001), abdominal muscle strength and endurance by times of sit-ups (13.6 7 9.1 number/min vs. 19.9 7 9.2; P ¼ 0.005), and flexibility of the lower back by sit and reach (18.8 7 10.8 cm vs. 27.8 7 10.9 cm; Po 0.001) of the patients who reached the target were improved significantly after 2-months of physical exercise training and education.We conclude that combination of dietary management and exercises are effective in improving health-related physical fitness, blood pressure control, dyslipidemia and renal function in overweight or obese CKD patients. Supportive individualized programs for lifestyle change could exert beneficial effects. A longitudinal study with larger sample size is warranted to elucidate the efficacy of combination of dietary management and exercises. Hypertension is a major cause of chronic kidney disease. Recent studies have shown that inflammation plays a critical role in the pathogenesis and progression of hypertensive kidney disease. However, the signaling mechanisms underlying the induction of inflammation are poorly understood. We have found that CXCL16, a recently discovered chemokine, is induced in the kidney in a murine model of angiotensin II (Ang II)-induced hypertension. Therefore, we examined whether CXCL16 regulates inflammatory cell infiltration and renal injury using CXCL16 knockout (CXCL16-KO) mice. Wildtype (WT) and CXCL16-KO mice were treated with Ang II via subcutaneous osmotic minipumps at 1500 ng/kg/min for up to 4 weeks. To accelerate renal injury, all mice were subjected to unilateral nephrectomy and received 1% NaCl in drinking water. WT and CXCL16-KO mice had virtually identical blood pressure at baseline. Ang II treatment led to an increase in blood pressure that is similar between WT and CXCL16-KO mice. Diabetic nephropathy is one of the most important causes of end stage renal disease (ESRD) in the world. Recently in a multicenter, randomized clinical trial performed in China, it was found that compound a-keto acid tablet in combination with low protein diet(LPDþKA) reduced proteinuria and delayed the progression to ESRD in Type 2 diabetic nephropthy(T2DN). However, the mechanisms underlined these effects were not been elucidated. This study is a part of the continuation of the study to explore the effects of LPDþ KA on podocyte as well as on local RAS in the kidney. A total of 60 patients with T2DN and CKD stages 3-4 are included in this study. All patients are treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day. The diet is randomly supplemented with keto-amino acids (Ketosterils, Fresenius Kabi) at a dosage of 100 mg/kg BW per day. The other 30 patients receive placebo. After six months of follow-up, protein intake differed only by 0.07 g/ kg/day between the two groups. The mean declines in GFR were 4.2 mL/min/ year (95%CI;2.9 to 5.5) in LPD group and 3.7 (95%CI; 2.7 to 4.7) in LPDþKA group. Compared with LPD, paitients in LPDþKA group had reduced proteinuria (2.1670.4 vs 3.5670.6 g/day; p/0.05). However, serum albumin and prealbumin levels did not change. Through further research we found that, after a median follow-up for six months, the urinary angiotensinogen:creatinine ratio in LPD patients was higher than in LPDþKA subjects (10.1 73.2 mg/g vs 5.8 7 1.2 mg/g; p/0.05);The urinary mRNA levels of the target genes nephrin, podocin and synaptopodin of podocyte were higher in the LPD group compared with LPDþKA(p/0.05) in urinary sediment, and the expression of nephrin, podocin and synaptopodin mRNA positively correlated with serum creatinine (r¼ 0.326, p ¼ 0.04; r ¼ 0.426, p ¼ 0.03; r ¼ 0.343, p ¼ 0.001, respectively) . In conclusion, compound a-keto acid tablet in combination with low protein diet (LPDþ KA) is associated with amelioration of proteinuria, better reduction in the loss of kidney function compared with LPD alone meanwhile nutrition status remained well. The mechanism under these effects may be explained by the role of LPDþ KA diet in reducing urine podocyte loss and lowering the angiotensinogen level in the urine. It is critical to preserve residual renal function (RRF) in CAPD, as RRF is associated with lower morbidity and mortality. low-protein diet supplemented with a-keto acids was reported to have an important roles in delaying in follow-up period progression of renal failure and relieving malnutritional status in non-dialysis patients with chronic renal failure. We evaluate the effects on the nutritional status and RRF of a low-protein diet supplemented with a-keto acids on CAPD patients prospectively. Seventy eight CAPD patients who were Abstracts: The 16th International Congress on Nutrition and Metabolism in Renal Disease 2012 A83
